JP2021534828A5 - - Google Patents

Info

Publication number
JP2021534828A5
JP2021534828A5 JP2021535496A JP2021535496A JP2021534828A5 JP 2021534828 A5 JP2021534828 A5 JP 2021534828A5 JP 2021535496 A JP2021535496 A JP 2021535496A JP 2021535496 A JP2021535496 A JP 2021535496A JP 2021534828 A5 JP2021534828 A5 JP 2021534828A5
Authority
JP
Japan
Prior art keywords
chimeric polypeptide
receptor
polychain
soluble
domain
Prior art date
Application number
JP2021535496A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020047299A5 (https=
JP7397874B2 (ja
JP2021534828A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/048881 external-priority patent/WO2020047299A1/en
Publication of JP2021534828A publication Critical patent/JP2021534828A/ja
Publication of JPWO2020047299A5 publication Critical patent/JPWO2020047299A5/ja
Publication of JP2021534828A5 publication Critical patent/JP2021534828A5/ja
Priority to JP2023203880A priority Critical patent/JP7735373B2/ja
Application granted granted Critical
Publication of JP7397874B2 publication Critical patent/JP7397874B2/ja
Priority to JP2025141061A priority patent/JP2025172844A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021535496A 2018-08-30 2019-08-29 多鎖キメラポリペプチドおよびその使用 Active JP7397874B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023203880A JP7735373B2 (ja) 2018-08-30 2023-12-01 多鎖キメラポリペプチドおよびその使用
JP2025141061A JP2025172844A (ja) 2018-08-30 2025-08-27 多鎖キメラポリペプチドおよびその使用

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US201862725010P 2018-08-30 2018-08-30
US201862725043P 2018-08-30 2018-08-30
US201862724969P 2018-08-30 2018-08-30
US62/725,010 2018-08-30
US62/725,043 2018-08-30
US62/724,969 2018-08-30
US201862746832P 2018-10-17 2018-10-17
US62/746,832 2018-10-17
US201862749007P 2018-10-22 2018-10-22
US62/749,007 2018-10-22
US201862749506P 2018-10-23 2018-10-23
US62/749,506 2018-10-23
US201962816683P 2019-03-11 2019-03-11
US62/816,683 2019-03-11
US201962817241P 2019-03-12 2019-03-12
US201962817230P 2019-03-12 2019-03-12
US62/817,230 2019-03-12
US62/817,241 2019-03-12
US201962881088P 2019-07-31 2019-07-31
US62/881,088 2019-07-31
PCT/US2019/048881 WO2020047299A1 (en) 2018-08-30 2019-08-29 Multi-chain chimeric polypeptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023203880A Division JP7735373B2 (ja) 2018-08-30 2023-12-01 多鎖キメラポリペプチドおよびその使用

Publications (4)

Publication Number Publication Date
JP2021534828A JP2021534828A (ja) 2021-12-16
JPWO2020047299A5 JPWO2020047299A5 (https=) 2022-08-24
JP2021534828A5 true JP2021534828A5 (https=) 2022-08-24
JP7397874B2 JP7397874B2 (ja) 2023-12-13

Family

ID=67928938

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021535496A Active JP7397874B2 (ja) 2018-08-30 2019-08-29 多鎖キメラポリペプチドおよびその使用
JP2023203880A Active JP7735373B2 (ja) 2018-08-30 2023-12-01 多鎖キメラポリペプチドおよびその使用
JP2025141061A Pending JP2025172844A (ja) 2018-08-30 2025-08-27 多鎖キメラポリペプチドおよびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023203880A Active JP7735373B2 (ja) 2018-08-30 2023-12-01 多鎖キメラポリペプチドおよびその使用
JP2025141061A Pending JP2025172844A (ja) 2018-08-30 2025-08-27 多鎖キメラポリペプチドおよびその使用

Country Status (11)

Country Link
US (8) US11518792B2 (https=)
EP (2) EP3844181B1 (https=)
JP (3) JP7397874B2 (https=)
KR (2) KR102877278B1 (https=)
CN (1) CN112996805A (https=)
AU (2) AU2019328290B2 (https=)
CA (1) CA3108949A1 (https=)
IL (1) IL280918B2 (https=)
SG (1) SG11202101779RA (https=)
TW (1) TWI851594B (https=)
WO (1) WO2020047299A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CN111315395A (zh) 2017-09-06 2020-06-19 耶鲁大学 白细胞介素-18变体和使用方法
US11401324B2 (en) 2018-08-30 2022-08-02 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
US11518792B2 (en) 2018-08-30 2022-12-06 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
CA3109361A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Single-chain and multi-chain chimeric polypeptides and uses thereof
CN120463822A (zh) 2018-09-27 2025-08-12 西里欧发展公司 掩蔽型细胞因子多肽
CN120924491A (zh) 2019-06-21 2025-11-11 免疫生物公司 多链嵌合多肽和其用途
WO2021163299A1 (en) * 2020-02-11 2021-08-19 HCW Biologics, Inc. Chromatography resin and uses thereof
CA3169243A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of activating regulatory t cells
AU2021220870A1 (en) 2020-02-11 2022-08-04 Immunitybio, Inc. Methods of treating age-related and inflammatory diseases
CN115836087A (zh) 2020-04-29 2023-03-21 Hcw生物科技公司 抗cd26蛋白及其用途
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
JP2023527869A (ja) * 2020-06-01 2023-06-30 エイチシーダブリュー バイオロジックス インコーポレイテッド 加齢関連障害の治療法
WO2021247003A1 (en) * 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
USD986799S1 (en) * 2020-09-11 2023-05-23 Wind Craft Aviation Inc. Aircraft
WO2022115865A2 (en) 2020-11-25 2022-06-02 Xilio Development, Inc. Tumor-specific cleavable linkers
GB202102049D0 (en) * 2021-02-13 2021-03-31 Psioxus Therapeutics Ltd Viruses
CN117120075A (zh) 2021-02-17 2023-11-24 库拉治疗股份有限公司 抗病原体白细胞介素-TGF-β受体融合多肽
WO2023006082A1 (zh) * 2021-07-30 2023-02-02 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
WO2023019215A1 (en) * 2021-08-11 2023-02-16 HCW Biologics, Inc. Multi-chain chimeric polypeptides and use thereof in the treatment of liver diseases
CN114042154B (zh) * 2021-12-14 2024-08-16 澳门大学 一种药物组合在制备抗肿瘤的联合治疗药物中的应用
US20250092140A1 (en) * 2022-01-14 2025-03-20 Shenghe (China) Biopharmaceutical Co., Ltd. Bispecific antibody binding to b7h3 and nkp30, and application thereof
JP2025508939A (ja) * 2022-03-02 2025-04-10 イミュニティーバイオ インコーポレイテッド 膵臓癌の治療方法
US20240075141A1 (en) 2022-03-18 2024-03-07 WUGEN, Inc. Chimeric receptor constructs for nk cells
US20230330228A1 (en) 2022-03-22 2023-10-19 WUGEN, Inc. Hybrid promoters, vectors containing same and methods of use
WO2023201311A1 (en) 2022-04-13 2023-10-19 HCW Biologics, Inc. Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder
JP7610308B2 (ja) * 2022-06-29 2025-01-08 メスキュージェナシス株式会社 ペプチド及び該ペプチドを含む会合体又は組成物
AU2024336545A1 (en) * 2023-09-08 2026-04-16 Northwestern University Chimeric antigen receptors with card domains
WO2025096644A1 (en) * 2023-10-31 2025-05-08 Immunitybio, Inc. Multi-chain chimeric polypeptides and use thereof in the treatment of advanced solid tumors
CN117924505B (zh) * 2024-03-25 2024-09-13 青岛宝迈得生物科技有限公司 一种重组hdac2蛋白单克隆抗体及其应用
WO2026043906A1 (en) * 2024-08-19 2026-02-26 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
US20260049118A1 (en) * 2024-08-19 2026-02-19 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
CN120289652B (zh) * 2025-04-16 2026-02-13 广东拓普灵生物医药科技有限公司 一种nk细胞的制备方法及其在肿瘤免疫治疗中的应用

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
AU702250B2 (en) 1994-07-11 1999-02-18 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US6117980A (en) 1997-02-21 2000-09-12 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US20060235209A9 (en) 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc TGF−βII型受容体に対するヒトモノクローナル抗体及びその医薬用途
AU2270101A (en) 1999-12-20 2001-07-03 Merck & Co., Inc. Pharmaceutical kit
ATE333900T1 (de) 2000-02-24 2006-08-15 Philogen Spa Zusamensetzungen und verfahren zur behandlung von angiogenese in pathologischen schädigungen
AU2001259215A1 (en) 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
ES2353273T3 (es) 2000-12-26 2011-02-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anticuerpos anti-cd28.
US20040204481A1 (en) 2001-04-12 2004-10-14 Pnina Fishman Activation of natural killer cells by adenosine A3 receptor agonists
US7371371B2 (en) 2001-08-13 2008-05-13 University Of Southern California Interleukin-2 mutants with reduced toxicity
TWI338009B (en) 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
WO2003104425A2 (en) 2002-06-07 2003-12-18 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Novel stable anti-cd22 antibodies
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
EP2357009A1 (en) * 2002-07-15 2011-08-17 Board of Regents, The University of Texas System Duramycin peptide binding to anionic phospholipids and aminophospholipids conjugates and their use in treating viral infections
JP4463104B2 (ja) 2002-08-30 2010-05-12 財団法人化学及血清療法研究所 ヒト抗ヒトインターロイキン−6抗体及び該抗体フラグメント
EP1400534B1 (en) 2002-09-10 2015-10-28 Affimed GmbH Human CD3-specific antibody with immunosuppressive properties
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
WO2004076488A1 (en) 2003-02-27 2004-09-10 Theravision Gmbh A molecule which binds cd80 and cd86
KR20060015482A (ko) 2003-03-21 2006-02-17 와이어쓰 인터루킨-21/인터루킨-21 수용체의 작용제를 이용한면역장애의 치료
JP4638876B2 (ja) 2003-05-23 2011-02-23 ワイス Gitrリガンド及びgitrリガンド関連分子及び抗体及びその使用
US9005613B2 (en) 2003-06-16 2015-04-14 Immunomedics, Inc. Anti-mucin antibodies for early detection and treatment of pancreatic cancer
JP2005124568A (ja) 2003-10-01 2005-05-19 Junichi Masuyama 細胞活性化方法及びこれを用いる細胞製造方法並びに医薬組成物
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
ES2375481T3 (es) 2004-03-30 2012-03-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticuerpos biespecíficos para elegir como diana células que participan en reacciones de tipo alérgico, composiciones y usos de los mismos.
WO2006086469A2 (en) 2005-02-08 2006-08-17 Genzyme Corporation Antibodies to tgfbeta
US7393833B2 (en) * 2005-03-09 2008-07-01 The Board Of Regents Of The University Of Oklahoma Chimeric proteins with phosphatidylserine binding domains
AU2006224313B2 (en) 2005-03-17 2011-08-11 Ucl Biomedica Plc Method for actvating Natural Killer cells by tumor cell preparation in vitro
CN100509849C (zh) 2005-04-07 2009-07-08 苏州大学 可溶性人cd28分子检测试剂盒及其应用
CN101203241B (zh) 2005-04-19 2012-02-22 西雅图基因公司 人源化抗-cd70结合物和其应用
CA2763671A1 (en) 2005-04-26 2006-11-02 Pfizer Inc. P-cadherin antibodies
ATE459648T1 (de) 2005-05-11 2010-03-15 Philogen Spa Fusionsprotein von antikörper l19 gegen fibronectin ed-b und interleukin 12
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
WO2009120922A2 (en) 2008-03-27 2009-10-01 Zymogenetics, Inc. Compositions and methods for inhibiting pdgfrbeta and vegf-a
LT3216803T (lt) 2008-06-25 2020-06-10 Novartis Ag Stabilūs ir tirpūs antikūnai, slopinantys vegf
NZ603698A (en) 2008-07-08 2014-03-28 Abbvie Inc Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
US9273136B2 (en) 2008-08-04 2016-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human anti-human NKG2D monoclonal antibodies
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
KR20120060877A (ko) 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
DE102009045006A1 (de) 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
AU2010306677B2 (en) 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011100538A1 (en) 2010-02-11 2011-08-18 Alexion Pharmaceuticals, Inc. Therapeutic methods using an ti-cd200 antibodies
WO2011127324A2 (en) 2010-04-08 2011-10-13 JN Biosciences, LLC Antibodies to cd122
WO2011155607A1 (ja) 2010-06-11 2011-12-15 協和発酵キリン株式会社 抗tim-3抗体
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
JP2012034668A (ja) 2010-08-12 2012-02-23 Tohoku Univ ヒト型化抗egfr抗体リジン置換可変領域断片及びその利用
CN107880136B (zh) * 2010-09-21 2021-11-12 阿尔托生物科学有限公司 多聚体il-15可溶性融合分子与其制造与使用方法
WO2012051147A1 (en) 2010-10-11 2012-04-19 Abbott Laboratories Processes for purification of proteins
CN102153653B (zh) 2010-12-30 2012-08-15 厦门大学 肿瘤血管靶向多肽与组织因子的融合蛋白及其制备方法
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
CN105884900A (zh) 2011-04-19 2016-08-24 梅里麦克制药股份有限公司 单特异性和双特异性抗igf-1r和抗erbb3抗体
SMT201800269T1 (it) 2011-04-25 2018-07-17 Daiichi Sankyo Co Ltd Anticorpo anti-b7-h3
SG10201603962TA (en) 2011-05-25 2016-07-28 Innate Pharma Sa Anti-kir antibodies for the treatment of inflammatory disorders
US8753640B2 (en) 2011-05-31 2014-06-17 University Of Washington Through Its Center For Commercialization MIC-binding antibodies and methods of use thereof
SG195253A1 (en) 2011-06-03 2013-12-30 Xoma Technology Ltd Antibodies specific for tgf-beta
WO2012170470A1 (en) 2011-06-06 2012-12-13 Board Of Regents Of The University Of Nebraska Compositions and methods for detection and treatment of cancer
CN103747803B (zh) 2011-06-22 2016-10-12 国家医疗保健研究所 抗axl抗体及其用途
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
AU2012335205A1 (en) 2011-11-11 2014-05-29 Rinat Neuroscience Corp. Antibodies specific for Trop-2 and their uses
EP4372084A3 (en) 2012-01-26 2024-08-14 Tecan Genomics, Inc. Compositions and methods for targeted nucleic acid sequence enrichment and high efficiency library generation
US10259626B2 (en) 2012-03-08 2019-04-16 Selig Sealing Products, Inc. Container sealing member with protected security component and removal tab
KR101535341B1 (ko) 2012-07-02 2015-07-13 한화케미칼 주식회사 Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도
CA2876285A1 (en) 2012-08-08 2014-02-13 Roche Glycart Ag Interleukin-10 fusion proteins and uses thereof
US20150218280A1 (en) 2012-08-10 2015-08-06 University Of Southern California CD20 scFv-ELPs METHODS AND THERAPEUTICS
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
WO2014033130A1 (en) 2012-08-28 2014-03-06 Institut Curie Cluster of differentiation 36 (cd36) as a therapeutic target for hiv infection
HUE033369T2 (en) 2012-11-20 2017-11-28 Sanofi Sa Anti-ceacam5 antibodies and uses thereof
WO2014095808A1 (en) 2012-12-17 2014-06-26 Delenex Therapeutics Ag Antibodies against il-1 beta
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
TW201446794A (zh) 2013-02-20 2014-12-16 Novartis Ag 利用抗-cd123嵌合抗原受體工程化t細胞之初級人類白血病有效靶向
WO2014159531A1 (en) 2013-03-14 2014-10-02 The Board Of Regents Of The University Of Texas System Monoclonal antibodies targeting epcam for detection of prostate cancer lymph node metastases
AU2014268364A1 (en) 2013-05-24 2015-12-10 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
JP2015030666A (ja) 2013-07-31 2015-02-16 学校法人順天堂 抗ヒトcd26モノクローナル抗体又はその抗原結合性断片
CN103709251B (zh) 2013-12-19 2016-04-13 江苏众红生物工程创药研究院有限公司 全人源抗cd26抗体及其应用
KR102127408B1 (ko) 2014-01-29 2020-06-29 삼성전자주식회사 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체
EP3099717B1 (en) 2014-01-31 2019-03-27 Novartis AG Antibody molecules to tim-3 and uses thereof
CA2937034A1 (en) 2014-02-03 2015-08-06 Riken Anti-tissue factor monoclonal antibody
FR3021970B1 (fr) 2014-06-06 2018-01-26 Universite Sciences Technologies Lille Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
AU2015305754B2 (en) 2014-08-19 2018-10-25 Merck Sharp & Dohme Llc Anti-tigit antibodies
MY193723A (en) 2014-08-29 2022-10-27 Hoffmann La Roche Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
JP7211703B2 (ja) 2014-12-22 2023-01-24 ザ ロックフェラー ユニバーシティー 抗mertkアゴニスト抗体及びその使用
US10744157B2 (en) 2015-03-26 2020-08-18 The Trustees Of Dartmouth College Anti-MICA antigen binding fragments, fusion molecules, cells which express and methods of using
KR20170138494A (ko) 2015-04-17 2017-12-15 엘살리스 비오떼끄 항-tyr03 항체 및 이의 용도
KR101778439B1 (ko) 2015-04-27 2017-09-14 울산대학교 산학협력단 자연살해세포 활성화제를 유효성분으로 함유하는 면역증강 및 항암활성증진용 조성물
US10723793B2 (en) 2015-06-12 2020-07-28 Ludwig Institute For Cancer Research, Ltd. TGF-β3 specific antibodies and methods and uses thereof
PT3328894T (pt) 2015-08-06 2019-02-13 Agency Science Tech & Res Anticorpos de cadeia comum gama/il2rbeta
KR20180061226A (ko) 2015-09-11 2018-06-07 와이즈에이씨가부시키가이샤 항cd26 항체와 다른 항암제를 조합한 암 치료용 조성물
CA2994858C (en) 2015-09-25 2024-01-23 Genentech, Inc. Anti-tigit antibodies and methods of use
CN108367071B (zh) 2015-11-13 2022-05-13 达纳-法伯癌症研究所有限公司 用于癌症免疫疗法的nkg2d-ig融合蛋白
JP2019511911A (ja) 2016-02-17 2019-05-09 ノバルティス アーゲー Tgfベータ2抗体
MX2018010445A (es) 2016-03-01 2019-10-17 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Anticuerpos especificos del receptor de poliovirus humano (rvp).
WO2017189526A1 (en) 2016-04-25 2017-11-02 Musc Foundation For Research Development Activated cd26-high immune cells and cd26-negative immune cells and uses thereof
ES3014658T3 (en) 2016-10-05 2025-04-23 Univ Central Florida Res Found Inc Methods and compositions related to nk cell and anti-pdl1 cancer therapies
CN118562016A (zh) * 2016-10-21 2024-08-30 艾尔特生物科技公司 基于多聚体il-15的分子
MX2019007981A (es) 2017-01-03 2019-10-15 Bioatla Llc Terapeutica de proteinas para el tratamiento de celulas senescentes.
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
CN110461357A (zh) 2017-02-28 2019-11-15 阿菲姆德股份有限公司 抗cd16a抗体与细胞因子的组合
CN117986384A (zh) 2017-03-06 2024-05-07 艾尔特生物科技公司 与il-12和il-18的基于il-15的融合物
EP3601538A4 (en) 2017-03-27 2021-03-10 Nantcell, Inc. ANK AND IL-12 COMPOSITIONS AND METHODS
EP3421607A1 (en) 2017-06-29 2019-01-02 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Identification and elimination of damaged and/or senescent cells
EP3676289B1 (en) 2017-08-28 2026-03-04 Altor BioScience, LLC Il-15-based fusions to il-7 and il-21
US11401324B2 (en) 2018-08-30 2022-08-02 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
CA3109361A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Single-chain and multi-chain chimeric polypeptides and uses thereof
US11518792B2 (en) 2018-08-30 2022-12-06 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
CN120924491A (zh) 2019-06-21 2025-11-11 免疫生物公司 多链嵌合多肽和其用途
WO2021163299A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Chromatography resin and uses thereof
AU2021220870A1 (en) 2020-02-11 2022-08-04 Immunitybio, Inc. Methods of treating age-related and inflammatory diseases
CA3169243A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of activating regulatory t cells
CN115836087A (zh) 2020-04-29 2023-03-21 Hcw生物科技公司 抗cd26蛋白及其用途
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
WO2023201311A1 (en) 2022-04-13 2023-10-19 HCW Biologics, Inc. Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder

Similar Documents

Publication Publication Date Title
JP2021534828A5 (https=)
JP2021534829A5 (https=)
JPWO2020047299A5 (https=)
JP2021534835A5 (https=)
JPWO2020047473A5 (https=)
JPWO2020047333A5 (https=)
TWI809130B (zh) 嵌合跨膜蛋白及其用途
CN109069537B (zh) 共刺激结构域中具有重复结合基序的car
US20250213708A1 (en) Chimeric transmembrane proteins and uses thereof
JP2021535225A5 (https=)
TW202016295A (zh) Car表現t細胞及car表現載體
CN109195985B (zh) Pd-1和4-1bb的融合蛋白
US10919950B2 (en) Tumor-specific IFNA secretion by car T-cells to reprogram the solid tumor microenvironment
JP2019513347A5 (https=)
JP2018519296A5 (https=)
CN111417652A (zh) 嵌合多肽及其用途
KR20180057720A (ko) 다가 Fv 항체
EP3365434A1 (en) Methods for culturing cells and kits and apparatus for same
CA3093518A1 (en) Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
KR20190046854A (ko) Bcma-특이적 피브로넥틴 iii 형 도메인을 포함하는 키메라 항원 수용체 및 그의 용도
CA3079076A1 (en) Methods and compounds for improved immune cell therapy
EP3728322A1 (en) Single- and multi-chain chimeric antigen receptors
CN112996819B (zh) 细胞分选系统及使用方法
CN111848818A (zh) 一种增强型免疫细胞及其应用
JPWO2020257639A5 (https=)